Boehringer Ingelheim To Initiate First Phase III Pivotal Study For New Oncology Compound BIBW 2992
Boehringer Ingelheim announced from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III pivotal trials in lung cancer with BIBW 2992, its novel, second generation, potent, irreversibly binding, dual inhibitor of EGFR and HER2 and thereby further demonstrated its commitment to discovery and development of novel compounds in oncology.
